Axogen (AXGN) Stock Could Be 27% Below Fair Value On Cash Flow

Simply Wall St.10-17 02:36

Axogen has been through a remarkable share price journey in recent years, which puts a spotlight on what investors are really paying for today. The question now is how well the current market value ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676511895?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987","is_english":true,"pubTime":"2026-10-17 02:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676511895","market":"hk","top_or_hot":-1,"title":"Axogen (AXGN) Stock Could Be 27% Below Fair Value On Cash Flow","media":"Simply Wall St.","content":"<div>\n<p>Axogen has been through a remarkable share price journey in recent years, which puts a spotlight on what investors are really paying for today. The question now is how well the current market value ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/axogen-axgn-stock-could-be-27-below-fair-value-on-cash-flow\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axogen (AXGN) Stock Could Be 27% Below Fair Value On Cash Flow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxogen (AXGN) Stock Could Be 27% Below Fair Value On Cash Flow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-17 02:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/axogen-axgn-stock-could-be-27-below-fair-value-on-cash-flow><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Axogen has been through a remarkable share price journey in recent years, which puts a spotlight on what investors are really paying for today. The question now is how well the current market value ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/axogen-axgn-stock-could-be-27-below-fair-value-on-cash-flow\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXGN","symbol_name":"AxoGen Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/axogen-axgn-stock-could-be-27-below-fair-value-on-cash-flow","article_id":"2676511895","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice1-card/1788954194987"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-axgn/axogen/news/axogen-axgn-stock-could-be-27-below-fair-value-on-cash-flow","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676511895","pubTimestamp":1792175818,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Axogen has been through a remarkable share price journey in recent years, which puts a spotlight on what investors are really paying for today. The question now is how well the current market value lines up with the cash flows that the business can generate over time.\n\nOver the past 3 years, Axogen has delivered a very large share price gain of roughly 7x, so recent buyers are effectively paying prices shaped by that run and not by a flat trading history.\nThe business focuses on nerve repair...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXGN":"AxoGen Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","SPHQ":"Invesco S&P 500 Quality ETF"},"translate_title":"Axogen (AXGN) 股票现金流可能比公允价值低 27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"AXGN":1.5,"SPHQ":0.72},"content_text":"Axogen has been through a remarkable share price journey in recent years, which puts a spotlight on what investors are really paying for today. The question now is how well the current market value lines up with the cash flows that the business can generate over time.  Over the past 3 years, Axogen has delivered a very large share price gain of roughly 7x, so recent buyers are effectively paying prices shaped by that run and not by a flat trading history. The business focuses on nerve repair solutions, so expectations around how efficiently it can turn that specialty into durable free cash flow may matter more than headline revenue growth when you think about intrinsic value. What if you looked at Axogen through its sales instead? See why Axogen's 8.3x P/S tells a different valuation story.  For investors, the debate is whether Axogen's current share price is adequately supported by the cash flows implied by its intrinsic value estimate using the Discounted Cash Flow (DCF) approach. If you want to test the same cash flow question that hangs over Axogen against a broader set of stocks, take a look at 33 high quality undervalued stocks. AdvertisementIs Axogen a Bargain on Cash Flow? The Discounted Cash Flow (DCF) model here looks at what Axogen might return to shareholders in cash over time and then pulls that back to today. On the latest twelve month numbers, Axogen is generating roughly $6.8 million of free cash flow, so the current $35.63 share price is being weighed against a business that is already throwing off some cash rather than just a concept. Where this DCF gets interesting is the projected ramp in free cash flow, which moves from single digit millions today to tens of millions per year within the next decade and assumes that growth gradually cools rather than staying aggressive. That profile suits a specialist in nerve repair solutions, where investors are often focused on the path to durable cash generation more than headline sales. The result is a set of cash flow projections that put Axogen's estimated intrinsic value meaningfully above the current share price, which is the gap this model is flagging for you to explore further. Find out what Axogen could be worth using our Discounted Cash Flow (DCF) estimate. The Axogen Narrative: What Would Justify Today's Price? Narratives for Axogen pick up where the valuation puzzle leaves off, explaining which paths for growth, profitability and earnings would need to occur for the stock to be worth meaningfully more or less than today's price on Simply Wall St's Community page. Instead of a single output from a ratio or model, Narratives describe the future assumptions behind that figure so you can watch how real world developments compare to it over time. One of the top community narratives on Axogen: 33% undervalued \"Upcoming FDA Biologics License Application approval for Avance Nerve Graft in September 2025 is expected to secure 12 years of market exclusivity...\" Discover why this Narrative puts Axogen at 33% undervalued. An unresolved piece of the Axogen story Cash flow models only go so far when the real-world outcome also depends on who is steering Axogen, how they are rewarded, and whether those incentives truly align with your interests. See who runs Axogen and how they are paid.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676511895","isCrawlerRequest":true}